Tonix Pharmaceuticals Holding Crecimiento futuro

Future controles de criterios 2/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Tonix Pharmaceuticals Holding de 6.9% y 51.4% respectivamente, mientras que el BPA crecerá en un 74.6% al año.

Información clave

6.9%

Tasa de crecimiento de los beneficios

74.6%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	24.6%
Tasa de crecimiento de los ingresos	51.4%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Low
Última actualización	14 May 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Previsiones de crecimiento de beneficios e ingresos

NasdaqCM:TNXP - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	45	-78	N/A	N/A	2
12/31/2025	18	-91	N/A	N/A	3
12/31/2024	12	-80	N/A	N/A	1
3/31/2024	10	-99	-91	-87	N/A
12/31/2023	8	-117	-110	-102	N/A
9/30/2023	4	-123	-114	-102	N/A
6/30/2023	N/A	-124	-121	-102	N/A
3/31/2023	N/A	-123	-132	-100	N/A
12/31/2022	N/A	-117	-146	-98	N/A
9/30/2022	N/A	-112	-167	-98	N/A
6/30/2022	N/A	-102	-156	-88	N/A
3/31/2022	N/A	-98	-141	-86	N/A
12/31/2021	N/A	-92	-111	-76	N/A
9/30/2021	N/A	-80	-81	-67	N/A
6/30/2021	N/A	-73	-80	-69	N/A
3/31/2021	N/A	-64	-69	-60	N/A
12/31/2020	N/A	-52	-57	-49	N/A
9/30/2020	N/A	-46	-45	-41	N/A
6/30/2020	N/A	-42	-33	-33	N/A
3/31/2020	N/A	-34	-27	-27	N/A
12/31/2019	N/A	-31	-27	-27	N/A
9/30/2019	N/A	-31	-27	-27	N/A
6/30/2019	N/A	-28	-25	-25	N/A
3/31/2019	N/A	-29	-26	-26	N/A
12/31/2018	N/A	-29	-24	-24	N/A
9/30/2018	N/A	-24	-22	-22	N/A
6/30/2018	N/A	-24	-22	-22	N/A
3/31/2018	N/A	-23	-21	-21	N/A
12/31/2017	N/A	-21	N/A	-19	N/A
9/30/2017	N/A	-23	N/A	-20	N/A
6/30/2017	N/A	-25	N/A	-23	N/A
3/31/2017	N/A	-30	N/A	-27	N/A
12/31/2016	N/A	-39	N/A	-37	N/A
9/30/2016	N/A	-45	N/A	-44	N/A
6/30/2016	N/A	-50	N/A	-48	N/A
3/31/2016	N/A	-52	N/A	-49	N/A
12/31/2015	N/A	-48	N/A	-43	N/A
9/30/2015	N/A	-44	N/A	-39	N/A
6/30/2015	N/A	-38	N/A	-31	N/A
3/31/2015	N/A	-32	N/A	-28	N/A
12/31/2014	N/A	-28	N/A	-23	N/A
9/30/2014	N/A	-22	N/A	-18	N/A
6/30/2014	N/A	-18	N/A	-16	N/A
3/31/2014	N/A	-14	N/A	-11	N/A
12/31/2013	N/A	-11	N/A	-9	N/A
9/30/2013	N/A	-10	N/A	-6	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que TNXP siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: Se prevé que TNXP siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: Se prevé que TNXP siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (32.1% al año) de TNXP crezcan más rápidamente que los del mercado US (8.1% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos (32.1% al año) de TNXP crezcan más rápidamente que un 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de TNXP se prevé que sea elevada dentro de 3 años.

Tonix Pharmaceuticals Holding Crecimiento futuro

Future controles de criterios 2/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Price target decreased to US$2.63

Recent updates

Tonix Pharmaceuticals Holding Corp., Annual General Meeting, May 02, 2024

Tonix Pharmaceuticals Holding Corp. has filed a Follow-on Equity Offering in the amount of $4.4 million.

Tonix Pharmaceuticals Announces Poster Presentation Describing Discovery of Novel Next-Generation Oxytocin Analogues At the American Chemistry Society (Acs) Spring 2024 Meeting

Tonix Pharmaceuticals Holding Corp. Announces Publication in Psychiatry Research Showing Activity of Bedtime TNX-102 SL on PTSD Symptoms and Sleep Quality in Military-Related PTSD at Four Weeks of Therapy

Tonix Pharmaceuticals Announces Translation of Preclinical Pharmacokinetic Parameters of TNX-1500 (Fc-modified humanized anti-CD40L mAb) Supports Monthly i.v. Dosing in Humans

Tonix Pharmaceuticals Completes Clinical Stage of Phase 1 Trial for TNX-1500 (Fc-Modified Humanized Anti-CD40L mAb) in Healthy Volunteers

Tonix Pharmaceuticals Reports Positive Phase 3 Study Results for Its Non-Opioid Painkiller in Late December

Tonix Pharmaceuticals Hosted KOL Webinar on Positive Phase 3 Fibromyalgia Trial for Tonmya™, Plans to File NDA for FDA Approval in Second Half of 2024

Tonix Pharmaceuticals Holding Corp. Announces FDA IND Clearance for DoD Funded Trial of TNX-102 SL for the Reduction of Acute Stress Response and Prevention of PTSD

Tonix Pharmaceuticals Presents Additional Data Highlighting the Favorable Tolerability and Differentiated Side Effect Profile of Tnx-102 Sl in Second Positive Phase 3 Clinical Trial for the Management of Fibromyalgia

Tonix Pharmaceuticals Holding Corp. has filed a Follow-on Equity Offering.

Tonix Pharmaceuticals Holding Corp. Announces Highly Statistically Significant and Clinically Meaningful Topline Results in Second Positive Phase 3 Clinical Trial of TNX-102 SL for the Management of Fibromyalgia

Tonix Pharmaceuticals Holding Corp. Announces IND Clearance by the FDA for Phase 2 Trial of TNX-2900 for the Treatment of Prader-Willi Syndrome, the Most Common Genetic Cause of Life-Threatening Childhood Obesity

Tonix Pharmaceuticals Holding Corp. Announces Enrollment Initiated in Mass General Brigham Phase 2 Investigator-Initiated Study of TNX-1900 (Intranasal Potentiated Oxytocin) for Bone Health in Children with Autism Spectrum Disorder

National Institute of Allergy and Infectious Diseases Selects Tonix Pharmaceuticals' Vaccine Candidate, TNX-1800, Selected by NIH/NIAID Project NextGen for Inclusion in Clinical Trials

Tonix Pharmaceuticals Holding Corp. Announces Topline Results from Phase 2 Proof-of-Concept Study of TNX-601 ER for the Treatment of Major Depressive Disorder

Tonix Pharmaceuticals Holding Corp. Completes Clinical Stage of Phase 2 PREVENTION Study of TNX-1900 for the Prevention of Migraine Headaches in Chronic Migraineurs

Tonix Pharmaceuticals Holding Corp. Receives a Letter from the Listing Qualifications Staff of the Nasdaq Stock Market

Tonix Pharmaceuticals Announces Publication of Data in the Journal Nature Involving Tnx-1500 (Fc-Modified Dimeric Anti-Cd40l Mab) for the Prevention of Rejection in Kidney Xenotransplantation in Animal Models

Tonix Pharmaceuticals Completes Clinical Stage of Phase 2 UPLIFT Study of TNX-601 ER for the Treatment of Major Depressive Disorder

Tonix Pharmaceuticals Announces Department of Defense Grant to Support the University of North Carolina’s Proposed Investigator Sponsored OASIS Trial of TNX-102 SL for Treatment of Acute Stress Reaction, Acute Stress Disorder, and Posttraumatic Stress Disorder

Tonix Pharmaceuticals Holding Corp. Announces Poster Presentation Showing Research Results for mTNX-1700

Tonix Pharmaceuticals Holding Corp. Announces Commitment to Supply Tosymra®? (Sumatriptan Nasal Spray) 10 Mg for Treatment of Acute Migraine

Tonix Pharmaceuticals Holding Corp. Announces Topline Results from Phase 2 Prevail Proof-Of-Concept Study of TNX-102 SL for the Management of Fibromyalgia-Type Long COVID

Tonix Pharmaceuticals Holding Corp. Announces Results of Pre-Ind Meeting with FDA for TNX-801 as A Potential Vaccine to Protect Against Mpox and Smallpox

Tonix Pharmaceuticals Initiates Phase 1 Trial of TNX-1500 (Fc-Modified Humanized Anti-Cd40l Mab) in Healthy Volunteers

Tonix Pharmaceuticals Completes Enrollment in Potentially NDA-Enabling Phase 3 RESILIENT Trial of TNX-102 SL for Management of Fibromyalgia

Tonix Pharmaceuticals Announces Enrollment Initiated in the MGH Phase 2 ‘STROBE’ Study of TNX-1900 (Intranasal Potentiated Oxytocin) for the Treatment of Binge-Eating Disorder

Tonix Pharmaceuticals Holding Corp. Announces Accelerating Completion of Enrollment in Phase 2 UPLIFT Study of TNX-601 ER (Racemic Tianeptine) for Major Depressive Disorder: Topline Data Now Expected in Fourth Quarter 2023

Tonix Pharmaceuticals Holding Corp. Announces Data Supporting Memory- and Cognition-Enhancing Effects of Racemic Tianeptine and (S)-Tianeptine, But Not (R)-Tianeptine, in Vivo Rat Novel Object Recognition Test

Tonix Pharmaceuticals Announces Initiation of Enrollment in the MGH Phase 2 ‘Power’ Study of TNX-1900 Intranasal Potentiated Oxytocin for the Treatment of Pediatric Obesity

Tonix Pharmaceuticals Holding Corp. (NasdaqCM:TNXP) and Tonix Medicines, Inc. entered into an agreement to acquire Certain Assets of Upsher Smith Laboratories, LLC for $25 million.

Tonix Pharmaceuticals Holding Corp. Announces Publication of Results from Phase 3 RELIEF Trial of TNX 102 SL for the Management of Fibromyalgia

Tonix Pharmaceuticals Holding Corp. Announces Data Presentations Involving TNX-1500 (Anti-CD40L mAb) for the Prevention of Rejection in Kidney and Heart Allograft Transplantation in Animal Models At the 2023 American Transplant Congress

Tonix Pharmaceuticals Holding Corp. Announces the Presentation of Data Detailing the Mechanism of Action and Pharmacokinetics of TNX-601 ER

Tonix Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement

Tonix Pharmaceuticals Holding Corp. Announces the Discovery Byscientists of the Isomers of Racemic Tianeptine

Tonix Pharmaceuticals Holding Corp. Announces Molecular Mechanism of Action of Tianeptine, the Active Ingredient of the Company's TNX-601 ER (Tianeptine Hemioxalate Extended-Release Tablets) Product Candidate

Tonix Pharmaceuticals Holding Corp. Announces U.S. Food and Drug Administration Cleared the Investigational New Drug Application to Support A Phase 1 Clinical Trial with TNX-1500

Tonix Pharmaceuticals Holding Corp. Announces Exclusive License of Potential Therapeutic or Preventative Fully Human and Murine Anti-SARS-CoV-2 Monoclonal Antibodies

Tonix Pharmaceuticals Holding Corp. Announces Publication of Paper in Viruses Highlighting the Company’S Development of A Vaccine to Protect Against Monkeypox and Smallpox (Tnx-801)

Tonix Pharmaceuticals Holding Corp. Initiates Enrollment in Phase 2 ‘PREVENTION’ Study of Potentiated Intranasal Oxytocin (TNX-1900) for the Prevention of Migraine Headaches in Chronic Migraineurs

Tonix Pharmaceuticals Holding Corp. (NasdaqCM:TNXP) entered into an agreement to acquire All of the assets of Healion Bio, Inc.

Tonix Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement

Tonix Pharmaceuticals Holding Corp. (NasdaqCM:TNXP) announces an Equity Buyback for $12.5 million worth of its shares.

Tonix Pharmaceuticals Holding Corp. Appoints Zeil Rosenberg, M.D., M.P.H., as Executive Vice President, Medical for Infectious Disease Programs

Tonix Pharmaceuticals Achieves Enrollment of First 50% of Participants in the RESILIENT Study

Tonix Pharmaceuticals Announces Exclusive License of Potential Therapeutic or Preventative Humanized Anti-Sars-Cov-2 Monoclonal Antibodies from Curia Global, Inc

Tonix Pharmaceuticals Holding Receives Letter from the Listing Qualifications Staff of the Nasdaq

Tonix Pharmaceuticals Holding Corp. announced that it expects to receive $14.25 million in funding

Tonix Pharmaceuticals Announces IND Clearance for TNX-601 ER as a Potential Treatment for Major Depressive Disorder

Tonix stock rises on FDA nod to start trial of TNX-601 for depression

Tonix Pharmaceuticals Holding Corp. Announces Data Presentations Involving TNX-1500 (Fc-Modified Anti-CD40L mAb) for the Prevention of Rejection in Allograft and Xenograft Transplantation in Animal Models at the International Congress of The Transplantation Society (TTS 2022)

Tonix Pharmaceuticals Holding Corp Initiates Enrollment in Phase 2 PREVAIL Study of TNX-102 SL for the Treatment of Long COVID

Tonix Pharmaceuticals GAAP EPS of -$1.22 beats by $0.23

Tonix Pharmaceuticals Holding Corp. Receives Cooperative Agreement Grant from the National Institute on Drug Abuse

Tonix Pharmaceuticals Holding Corp. to Report Q2, 2022 Results on Aug 08, 2022

Tonix announces partnership to study monkeypox vaccine in 1H 2023

Tonix Pharmaceuticals Holding Corp. Announces Appointment of Sina Bavari, Ph.D. as Executive Vice President, Infectious Disease Research and Development

Tonix Pharmaceuticals Holding Corp. Announces Development of TNX-601 ER

Tonix Pharma to develop extended-release form of depression therapy

Tonix Pharmaceuticals Holding Corp. Announces Trial Design of New Phase 2 Clinical Study of TNX-1300 for Cocaine Intoxication

Tonix Pharmaceuticals Holding Corp. announced that it expects to receive $28.5 million in funding

Is Tonix Pharma's Stock A Buy Or Sell After Buyback Plan Announcement?

Tonix Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement

United States Patent and Trademark Office Issues U.S. Patent to the Tonix Pharmaceuticals Holding Corp

Tonix Pharmaceuticals Holding Corp. (NasdaqCM:TNXP) announces an Equity Buyback for $12.5 million worth of its shares.

Tonix Pharmaceuticals Approves Reverse Stock Split with Intend to Increase the Per Share Trading Price of Common Stock to Satisfy Minimum Bid Price Requirement for Continued Listing on NASDAQ

Tonix Pharmaceuticals Holding Corp. Announces Results of Retrospective Observational Database Study In Over 50,000 Long COVID Patients

Tonix Pharmaceuticals Holding Corp. Initiates Enrollment in the Resilient Study, A Potentially Pivotal Phase 3 Study of TNX-102 SL for the Management of Fibromyalgia

Tonix Pharmaceuticals Announces IND Clearance for TNX-102 SL as A Potential Treatment for Long Covid Syndrome, Also Known as Post-Acute Sequelae of Covid-19

Price target decreased to US$2.63

Daniel Goodman Not to Stand for Re-Election at Tonix Pharmaceuticals Holding Corp.'s 022 Annual Meeting of Stockholders

Tonix Pharmaceuticals Initiates Enrollment in Clinical Trial of TNX-2100, a Diagnostic Skin Test to Measure Functional T Cell Immunity to SARS-CoV-2